Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Red Blood Cell 2,3-biphosphoglycerate Levels in Patients Treated With Empagliflozin. A Prospective Cohort Study.

NCT06284850 is registered in ClinicalTrials.gov with Aristotle University Of Thessaloniki as lead sponsor.

NCT NCT06284850
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06284850 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Red Blood Cell 2,3-biphosphoglycerate Levels in Patients Treated With Empagliflozin. A Prospective Cohort Study.
Lead sponsor
Aristotle University Of Thessaloniki
Phase
Observational
Overall status
Unknown status
Start date
November 30, 2023
Completion date
November 30, 2025
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cardiovascular prevention, empagliflozin, hematocrit change, sglt2-inhibitors, tissue oxygenation